Key result
EXP3174 lowers mean arterial pressure by ~23% without compromising myocardial blood flow.
Why the study?
The role of the renin-angiotensin system in regulation of myocardial tissue perfusion and the comparative systemic and coronary effects of the AT1 receptor antagonist EXP3174 versus the ACE inhibitor enalaprilat were unclear.
Does EXP3174 alter systemic and coronary hemodynamics or regional myocardial blood flow compared to enalaprilat in anesthetized dogs?
Does EXP3174 alter systemic and coronary hemodynamics or regional myocardial blood flow compared to enalaprilat in anesthetized dogs?
Blockade of the AT1 receptor by EXP3174 induces hemodynamic modifications similar to the ACE inhibitor enalaprilat, but neither affects regional myocardial blood flow, suggesting the RAS does not regulate myocardial tissue perfusion in this model.
Answers are grounded in this paper and cite their sources.
Suggests AT1 blockade mimics ACE inhibition hemodynamically without coronary effects in dogs; leaves open whether RAS regulates myocardial perfusion in patients.
The effects of EXP3174 (0.03-0.3 mg/kg), the active metabolite of the angiotensin II (AII) receptor antagonist losartan, on systemic and coronary hemodynamics as well as on regional myocardial blood flow (radioactive microspheres) were evaluated in anesthetized, open-chest dogs with or without preactivated renin-angiotensin system (RAS) (furosemide treatment). These effects were compared with those of the angiotensin-converting enzyme (ACE) inhibitor enalaprilat (0.1-1 mg/kg). In dogs without preactivated RAS, EXP3174 or enalaprilat did not exert marked hemodynamic effects other did not exert marked hemodynamic effects other than a significant decrease in mean arterial blood pressure (MAP) at the highest doses. In dogs with preactivated RAS, EXP3174 induced a marked, dose-dependent decrease in MAP (maximum decrease -23 +/- 7%), associated with a significant decrease in total peripheral resistance (TPR), whereas cardiac output (CO), heart rate (HR), and left ventricular dP/dt remained unchanged. At the coronary level, EXP3174 induced a decrease in mean coronary resistance that paralleled that of AP. Similar systemic and coronary hemodynamic effects were obtained with enalaprilat administered at doses three times higher. However, regional myocardial tissue perfusion, assessed by the microspheres technique (whether subendocardial, subepicardial, or transmural) or its transmural distribution (endo/epi ratios) was not affected by EXP3174 or enalaprilat. Thus, these results indicate that blockade of the AT1 receptor of AII by EXP3174 induces hemodynamic modifications similar to those evoked by the ACE inhibitor enalaprilat. The lack of effect of EXP3174 or enalaprilat on regional myocardial blood flow (RMBF) suggests, however, that the RAS does not play a role in regulation of myocardial tissue perfusion.
No takes yet. Share an insight, caveat, or question.
Richard et al. (1993) studied Preactivated renin-angiotensin system. EXP3174 vs. Enalaprilat (0.1-1 mg/kg) was evaluated on Systemic and coronary hemodynamics and regional myocardial blood flow. In dogs with preactivated RAS, EXP3174 induced a dose-dependent decrease in mean arterial blood pressure similar to enalaprilat, without affecting myocardial blood flow.
Synapse has enriched 10 related papers. Consider them for comparative context: